Precision Medicine

Computational biology can fuel collaboration across the clinical and research enterprise, enhance projects, and does not require lab space. Weill Cornell Medicine (WCM) has centralized institutional efforts through the Caryl and Israel Englander Institute for Precision Medicine (EIPM) at WCM. This translational research hub opened in 2013 goal is to pinpoint the molecular basis of disease in individual patients, to identify patient-specific optimal therapeutic strategies, and to spur the discovery of novel therapies. The EIPM brings together a diverse multi-disciplinary team that includes clinicians, basic scientists, pathologists, molecular biologists, and computational biologists. The Institute’s three main resources, next generation genomics, bio banking and computational biology, enable its team to efficiently match new, biologically-targeted therapies to the cancer patients who will benefit most. The CTSC and EIPM are close collaborators, with Dr. Oliver Elemento Director of the Englander Institute for Precision Medicine EIPM serving as the CTSC Associate Program Director. Under Dr. Elemento’s leadership, EIPM’s primary mission is to uncover the molecular roots of disease using genomic sequencing, informatics, and other technologies, empowering WCM investigators to expand their research focus, taking the precision medicine methodology they pioneered in cancer and applying it to other areas of research including cardiovascular disease, lung disease, diabetes and neurological disease.

Clinical & Translational Science Center 1300 York Ave., Box 149 New York, NY 10065